At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 154 enrolled
Drug / intervention
OPC-12759 Ophthalmic suspensiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Administration Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients
In Brief
A Phase 3 clinical trial evaluating OPC-12759 Ophthalmic suspension for Dry Eye Syndromes. Completed, enrolled 154 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate safety and efficacy of OPC-12759 ophthalmic suspension during 52 weeks in dry eye patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedJan 2009
Primary CompletionSep 2010
Study CompletionJan 2011
TodayJul 2026
First PostedJan 7, 2009
Enrollment StartJan 1, 2009
Primary CompletionSep 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.5 years ago
Interventions
OPC-12759 Ophthalmic suspensiondrug
Instillation,4times/day,for 52weeks